Human Urinary GM2-activator Protein as a Potential Biomarker for Lung Cancer

Laddawan Potprommanee1,2, Haou-Tzong Ma1, Chein-Hung Chen1, Paitoon Aobchey4, Kongsak Boonyapranali5, Busyasam Chewaskulyong3, Padchanee Sangthong1, Lalida Shank1 and Shui-Tein Chen1,3,7*

1Institute of Biological Chemistry, Academia Sinica, Taipei 115, Taiwan
2Department of Chemistry, Faculty of Science, Chiang Mai University, Chiang Mai 50200, Thailand
3Genomics Research Center, Academia Sinica, Taipei 115, Taiwan
4Science and Technology Research Institute, Chiang Mai University, Chiang Mai 50200, Thailand
5Faculty of Medical Science, Nakhonratchasima College, Nakhonratchasima 30000, Thailand
6Oncology Unit, Department of Medicine, Chiang Mai University, Chiang Mai 50200, Thailand
7Institute of Biochemical Science, College of Life Science, National Taiwan University, Taipei 115, Taiwan

Abstract

Human urine can be obtained from most patients by noninvasive ways of collection. It is a rich source of biomarkers for diagnostic tests, therapeutic guidance and prognostic information for patients and clinicians. Recently, the protein expression pattern of urine samples from lung cancer patients and healthy controls were compared using two-dimensional gel electrophoresis (2-DE). GM2 activator protein (GM2AP) in lung cancer patients with 2.5-4.0 folds higher than that found in healthy controls was the protein of interest, and this protein was focused because it is related to tumor-associated gangliosides found in cancer progression. The aim of this study was to investigate the urinary biomarkers associated with lung cancer. First, we applied proteomic approach to confirm the increase level of GM2AP in urine samples from lung cancer patients and healthy controls. Then, the expression level of urinary GM2AP was quantified using Western blotting and Enzyme-Linked Immunosorbent Assay (ELISA). The results show that the expression level of GM2AP significantly increased in each subtype of lung cancer patients (P<0.05). In addition, nano liquid chromatography coupled online with tandem mass spectrometry (NanofLC-MS/MS) provided evidence of an increase of GM2AP with the glycan structure identification from doubly charged at m/z 1202.1025 corresponding to the structure of (Hex)4(HexNAc)3(Fuc) linked with peptide (PIIVGDNVTLSVVG). Overall data suggested that the GM2AP may be associated with lung cancer and may be useful as a marker to monitor lung cancer prognosis.

Keywords: Biomarker; Lung cancer; GM2 activator protein; Human urine; Glycan structure

Introduction

Lung cancer is the most common cause of cancer–related mortality worldwide in male and female, accounting for 28% of all male cancer deaths and 26% of all female cancer deaths in the United States in 2013 [1]. Many patients with lung cancer are in the advanced stages of the disease at the time of diagnosis [2]. However, the poor early detection of lung cancer and ineffective treatments for advanced disease are responsible for the low overall 5-year survival rate of only 14% [3]. Therefore, the development of noninvasive diagnostic tools for discovery of novel lung cancer specific biomarker is emerging as an important to identify early stage of lung cancer and therapeutic applications. Proteomic techniques including two-dimensional gel electrophoresis (2-DE) and differential gel electrophoresis coupled with MS technology are useful for the analysis of tumor markers [4-8]. Recently, different proteomic approaches have been used for biomarker discovery in urine samples of lung cancer patients [9-12]. All of these studies have provided interesting data that contributed to enrich the urinary proteomic map of lung cancer patients. Tantipagbownong et al. [12] studied urinary proteome changes between lung cancer patients and healthy controls by 2-DE. Several differentially expressed proteins were identified as potential biomarkers.

The objective of this study was to identify urinary biomarker for lung cancer. Urinary proteome analysis of lung cancer patients compared to healthy controls showed an increase of GM2AP, which was confirmed by Western blot analysis. We decided to focus our study on this protein due to reports of this protein being an essential cofactor for the degradation of ganglioside GM2 to GM3 by lysosomal β-hexaminidase A (Hex A) [13,14]. This protein is also associated with the changing level of ganglioside and tumor-associated gangliosides found in cancer progression [15-17]. The aberrant of gangliosides in tumor cell induced tumor angiogenesis through regulation of growth factor signaling [18,19]. Quantification of GM2AP in urine of lung cancer patients and healthy controls by ELISA confirmed a significant increase of GM2AP in lung cancer cases. However, the structure and function information available for this activator are still not well understood. Investigation of alterations in glycan structures of GM2AP in cancer patients may lead to better understanding of how glycosylation modulates the biological activities of glycoproteins in lung cancer, which could be useful as a marker for the diagnosis and prognosis of lung cancer.

Materials and Methods

Sample collection

Human urine samples from forty-four healthy individuals and
In-gel enzymatic digestion

Protein spots were manually excised from the gels, washed twice with 50% acetonitrile (ACN) in 25 mM ammonium bicarbonate, pH 8.0 for 15 min and dried in 100% ACN. The proteins in the spots were reduced with 10 mM DTT in 25 mM ammonium bicarbonate at 56°C for 45 min, and alkylated with 55 mM IAA at room temperature for 30 min in the dark. The gel pieces were washed twice with 50% ACN in 25 mM ammonium bicarbonate buffer for 15 min each and dried in 100% ACN. Dried gel pieces were swollen in 25 mM ammonium bicarbonate containing trypsin and chymotrypsin and incubated at 37°C for at least 16 h. Peptides were subsequently extracted three times with 50% ACN in 1% trifluoroacetic acid (TFA). The extracted solutions were combined and dried using a SpeedVac concentrator (Labogene ApS, Lyngby, Denmark). The digested peptides were desalted with a C18 ZipTip (Millipore, Bedford, MA, USA). Bound peptides were eluted from the ZipTip with 50% ACN in 0.1% TFA.

Western blot analysis and lectin staining

In total, 15 µg of urine samples were present in sample buffer composed of 50 mM Tris pH 8.0, 10% glycerc, 2% SDS, betamercaptoethanol and 0.1% bromophenol blue. The mixed samples were heated at 95°C for 10 min and subsequently fractionated on 15% SDS-PAGE. After SDS-PAGE, proteins were transferred onto polyvinylidene fluoride (PVDF) (Millipore, Bedford, MA, USA) membranes using a semi-dry apparatus (Amersham Biosciences, USA). For 2-DE Western blot, the first and 2-DE separations were performed as described above and also transferred onto PVDF membranes. The membranes were blocked for 2 h at room temperature with 5% BSA in PBS containing 0.05% Tween 20 (PBST), followed by incubation with rabbit polyclonal anti-human GM2AP primary antibody (1:1000 dilution, Abcam, Cambridge, UK) for 2 h at room temperature. After washing with PBST three times for 10 min each, the primary antibody was detected with an anti-rabbit HRP-conjugated secondary antibody (1:5000 dilution, Abcam, Cambridge, UK) for 1 h at room temperature, washed with PBST three times for 10 min each. The blot was developed with an enhanced chemiluminescence Western blotting detection system (ECL™; kit; PerkinElmer) and exposed to Fujifilm LAS-4000 Luminescent Image Analyzer (FUJIFILM Corporation, Japan).

For lectin staining, the PVDF membranes were washed three times with PBST and incubated with 5% BSA in PBST for 2 h at room temperature. The membranes were washed three times with PBST, followed by staining with 10 µg/mL biotin-conjugated aleuria aurantia lectin (AAL) (Burlingame, CA, USA) for 2 h at room temperature and washed three times with PBST. Then, the membranes for lectin blotting were incubated with streptavidin-conjugated HRP (10 µg/mL) for 1 h and washed three times with PBST. The membranes were developed with an enhanced chemiluminescence Western blotting detection system.

ELISA assay

Human GM2AP in urine samples from lung cancer patients and healthy controls were analyzed using commercially available sandwich immunoassay from Uscln Life Science Inc., according to the instruction manual provided by the manufacturer. The sensitivity limit of the GM2AP assay was 0.156-10 ng/mL. Briefly, 100 µL of the diluted standard and samples were added in duplicate to the well of a microtiter plate coated with an antibody specific to GM2AP. Dilution buffer alone was added to a pair of duplicate well to serve as blank. After incubation at 37°C for 2 h, 100 µL of biotin-conjugated antibody specific to GM2AP was added to each well and incubated at 37°C for 1 h. The plate was washed three times with the wash solution, followed by...
incubation with 100 µL of avidin conjugated HRP at 37°C for 30 min. After washing with the wash solution three times, 90 µL of substrate solution was added to each well. The plate was covered with aluminum foil to protect from light and incubated for 20 min to allow for color development. The reaction was stopped by the addition of 30 µL of stop solution and the optical densities were determined using absorbance at 450 nm. The urinary GM2AP concentration was calculated from a standard curve.

**Electro-elution for intact protein mass determination**

The GM2AP spots of lung cancer were excised from 2-DE gels and extracted by electro-elution using Midi GeBaflex-tube (MW cut off at 3.5 kDa) (Gene Bio-Aplication, Israel) according to instruction manual provided by the manufacturer. Following electroelution, salts, SDS and dye were removed by dialysis using the same electroelution tubes. The proteins were then concentrated in a vacuum centrifuge for subsequent MALDI-TOF/MS analysis to determine precise molecular mass of GM2AP. Protein was identified by comparison of the observed mass with the predicted mass obtained from the Swiss-Prot entries for those proteins that had been identified by MALDI-TOF peptide mass fingerprinting.

**MALDI-TOF mass analysis**

For mass spectrum analysis, one micro-liter of each protein sample were mixed with equal volume of matrix solution consisting of 2,5-dihydroxybenzoic acid (50 nmol/µL in 50% ACN). One micro-liter of the resulting mixture was spotted onto a 384-well MALDI target plate and allowed to air dry at room temperature. After crystallization, the sample was deposited manually on top of the matrix and vacuum-dried. Analysis was performed on an Ultraflex II MALDI-TOF/TOF mass spectrometer (Bruker Daltonik GmbH, Bremen, Germany). Mass spectra were obtained in the range of mass to charge ratio (m/z) from 10,000 to 30,000.

**NanoLC-MS/MS analysis**

High resolution and high mass accuracy nanoflow LC-MS/MS/MS experiments were performed on a LTQ Orbitrap XL ETQ mass spectrometer (Thermo Fisher Scientific, San Jose, CA, USA) equipped with a nanoelectrospray ion source (New Objective, Inc.), an Agilent 1100 Series binary high-performance liquid chromatography pump (Agilent Technologies), and a Famos autosampler (LC Packings). The digestion solution (6 µL) was injected onto a self packed precolumn (150 µm I.D. x 30 mm, 5 µm, 200 Å) operating at a flow rate of 10 µL/min. Chromatographic separation was performed on a self packed reversed phase C18 nano-column (75 µm I.D. x 200 mm, 3 µm, 200 Å) using 0.1% formic acid in water as mobile phase A and 0.1% formic acid in 80% ACN as mobile phase B operated at 300 nL/min flow rate. Electro-spray voltage was maintained at 1.8 kV and capillary temperature was set at 200°C. Survey full-scan MS conditions were at mass range (m/z) of 320-2000 and the resolution of the mass spectrometer was set to 30,000. The three most intense ions were sequentially isolated for higher-energy C-trap Dissociation (HCD) at resolution of 7500 to 30,000. The three most intense ions were sequentially isolated for (m/z) of 320-2000 and the resolution of the mass spectrometer was set to 30,000. The three most intense ions were sequentially isolated for subsequent MALDI-TOF/MS analysis to determine precise molecular mass of GM2AP. Protein was identified by comparison of the observed mass with the predicted mass obtained from the Swiss-Prot entries for those proteins that had been identified by MALDI-TOF peptide mass fingerprinting.

**Electro-elution for intact protein mass determination**

The GM2AP spots of lung cancer were excised from 2-DE gels and extracted by electro-elution using Midi GeBaflex-tube (MW cut off at 3.5 kDa) (Gene Bio-Aplication, Israel) according to instruction manual provided by the manufacturer. Following electroelution, salts, SDS and dye were removed by dialysis using the same electroelution tubes. The proteins were then concentrated in a vacuum centrifuge for subsequent MALDI-TOF/MS analysis to determine precise molecular mass of GM2AP. Protein was identified by comparison of the observed mass with the predicted mass obtained from the Swiss-Prot entries for those proteins that had been identified by MALDI-TOF peptide mass fingerprinting.

**MALDI-TOF mass analysis**

For mass spectrum analysis, one micro-liter of each protein sample were mixed with equal volume of matrix solution consisting of 2,5-dihydroxybenzoic acid (50 nmol/µL in 50% ACN). One micro-liter of the resulting mixture was spotted onto a 384-well MALDI target plate and allowed to air dry at room temperature. After crystallization, the sample was deposited manually on top of the matrix and vacuum-dried. Analysis was performed on an Ultraflex II MALDI-TOF/TOF mass spectrometer (Bruker Daltonik GmbH, Bremen, Germany). Mass spectra were obtained in the range of mass to charge ratio (m/z) from 10,000 to 30,000.

**NanoLC-MS/MS analysis**

High resolution and high mass accuracy nanoflow LC-MS/MS/MS experiments were performed on a LTQ Orbitrap XL ETQ mass spectrometer (Thermo Fisher Scientific, San Jose, CA, USA) equipped with a nanoelectrospray ion source (New Objective, Inc.), an Agilent 1100 Series binary high-performance liquid chromatography pump (Agilent Technologies), and a Famos autosampler (LC Packings). The digestion solution (6 µL) was injected onto a self packed precolumn (150 µm I.D. x 30 mm, 5 µm, 200 Å) operating at a flow rate of 10 µL/min. Chromatographic separation was performed on a self packed reversed phase C18 nano-column (75 µm I.D. x 200 mm, 3 µm, 200 Å) using 0.1% formic acid in water as mobile phase A and 0.1% formic acid in 80% ACN as mobile phase B operated at 300 nL/min flow rate. Electro-spray voltage was maintained at 1.8 kV and capillary temperature was set at 200°C. Survey full-scan MS conditions were at mass range (m/z) of 320-2000 and the resolution of the mass spectrometer was set to 30,000. The three most intense ions were sequentially isolated for higher-energy C-trap Dissociation (HCD) at resolution of 7500 to 30,000. The three most intense ions were sequentially isolated for (m/z) of 320-2000 and the resolution of the mass spectrometer was set to 30,000. The three most intense ions were sequentially isolated for subsequent MALDI-TOF/MS analysis to determine precise molecular mass of GM2AP. Protein was identified by comparison of the observed mass with the predicted mass obtained from the Swiss-Prot entries for those proteins that had been identified by MALDI-TOF peptide mass fingerprinting.

**Identification of GM2AP as a biomarker of lung cancer**

To verify the cancer selective character of candidate proteins identified by mass spectrometry, the antibody-binding capacity of spot corresponding to GM2AP protein was investigated by 2-DE Western blot of healthy control and lung cancer patient to confirm the identity of the protein spot matched after 2-DE using antibodies GM2AP, which is shown in the Supporting Information Figure S2. Data suggested that GM2AP was over-expressed in lung cancer patients, consistent with the increase in protein spot intensity observed in the 2-DE gel. In addition, the expression level of GM2AP in lung cancer urine samples (n=48) was validated by Western blot analysis to compare their GM2AP levels with those of healthy controls (n=48). Figure 2A is a representative panel of urinary GM2AP profile from the four subtypes of lung cancer patients and healthy controls. The level of GM2AP was significantly increased in the each subtype of lung cancer patients when compared to the mean of healthy controls (Figure 2B, P<0.05). Western blot is a semi-quantitative method, hence ELISA was used to quantify the expression level of GM2AP in urine of healthy controls (n=44) and lung cancer patients (n=48). The patients included 33 male and 15 female individuals. The mean age of the patients was 53.3 years (range, 28-74). The mean of GM2AP level in all of lung cancer patients were measured to be 1.60 ± 1.21 ng/mL, whereas the mean of GM2AP level for healthy controls was 0.21 ± 0.14 ng/mL. There was a significantly increase in the GM2AP level for patients compared to healthy controls (P<0.05), that is about 7.62 fold increase on the median (Figure 3).
The urinary GM2AP level measured in the male patients (1.16 ± 1.07 ng/mL) was higher than that measured in the female patients (1.13 ± 1.05 ng/mL). According to histologic type, the urinary GM2AP level measured in patients with adenocarcinoma, small cell lung cancer and squamous cell carcinoma were 1.25 ± 1.12, 1.48 ± 1.35 and 2.27 ± 2.20 ng/mL, respectively. The urinary GM2AP level was measured to be 1.69 ± 1.54 and 0.63 ± 0.38 ng/mL in patients with stage III and IV, respectively. The expression levels of GM2AP of all the patients were included in the statistical analysis and significant correlation (P<0.05) was found with histology cancer type, whereas gender and pathologic stage were not correlated (Table 1).

Detection of intact protein mass of GM2AP in lung cancer

To confirm the molecular mass of GM2AP in lung cancer patient, the GM2AP spot in 2-DE gel were excised and applied to electro-elution for MALDI-TOF/MS as described in experimental procedure. The protein mass spectrum of GM2AP appeared as one major peak at 18663 Da for urine samples obtained from lung cancer patients. This was significantly greater than the predicted GM2AP mass of 17589 Da (data not shown), thus suggesting post-translational modifications (PTM).

The PTM of GM2AP has been identified as glycosylation. We then investigated the difference of GM2AP glycan moiety in healthy control and cancerous urine with lectin staining, which was performed on the 2-DE Western blotting. AAL lectin signaling was increased fucosylated urinary GM2AP in lung cancer patient compared to that of healthy control (Supporting Information Figure S3).

Determination the glycan structure of GM2AP in lung cancer

In order to determine the glycan structure of GM2AP, the GM2AP spots from 2-DE were in-gel digested with trypsin and chymotrypsin. The resulted peptides were further analyzed by nanoLC-MS/MS. The
mass spectra showed the oxonium ion at m/z 204.087 and Y1 ion, peptide with a HexNac was present in HCD. The parent ion at m/z 1202.1025 and peptide molecular mass of 1363.813 Da (PIIVPGNVTLSVVG) of GM2AP was calculated; in the meantime, glycan composite (Hex)(HexNAc)(Fuc) also been determined as shown in Figure 4.

Discussion

The human proteome is the entire set of proteins expressed by a genome, cell, tissue and organism at any given time. The proteome of an organism, tissue or even a single type of cells is much more complex than its corresponding genome. This is mostly due to alternate splicing, post-translational processing and different patterns of protein modification which affect virtually all proteins. Due to proteomes complexity, their analysis is extremely challenging. Therefore, it can potentially overcome some limitations of other approaches to identify new marker molecules for many diseases. Moreover, the proteins secreted from tumor cells are potential biomarkers for disease diagnosis and prognosis. Tantipaboontwong et al. [12], a former researcher in our group, first used 2-DE and MALDI-TOF/MS in search of urinary biomarkers of lung cancer and reported six up-regulated protein spots and three down-regulated protein spots in lung cancer urine samples compared to the controls. GM2AP in lung cancer patients was present with 2.5-4.0 fold higher than that found in healthy controls, hence was the protein of interest. Our objective was not to draw up a list of differentially expressed spots, but to identify proteins that would be relevant to the prediction of lung cancer. To reach this objective, we first used 2-DE to confirm the up-regulation of GM2AP in urine samples from lung cancer patients. We found that the expression level of GM2AP in both of the pooled and individual samples with different subtypes of lung cancer patients were significantly increased compared to that of healthy controls (Figure 1A and B). This result was confirmed by Western blotting in the 2-DE region suggesting that the expression level of GM2AP in lung cancer patients was higher than in healthy controls.

In this study, we then focused on the GM2AP which was significantly increased in urine of lung cancer patients. GM2AP is a small monomeric protein containing a single site for Asn linked glycosylation

![Figure 2: Quantification of the GM2AP in lung cancer patients and healthy donors are subjected to 15% SDS-PAGE and blotted with anti-GM2AP antibody. (A) Western blotting analyses of four representative lung cancer patients in four subtypes are showed (lanes 1-4); AD: Adenocarcinoma, SC: Small cell lung cancer, SQ: Squamous cell carcinoma and UN: Other types of carcinoma and from a representative of healthy donors (lanes 5-8). (B) Scatter plot of the relative intensities of GM2AP quantified in urine from healthy controls (n = 44) and different types of lung cancer patients (n = 48) in urine samples; N: Healthy control, AD: Adenocarcinoma, SC: Small cell lung cancer, SQ: Squamous cell carcinoma, UN: Other type of carcinoma. Black bars indicate the average levels for GM2AP in each subtype of lung cancer patients. *: P value < 0.05 compared to the value for the healthy urine samples.](image)

![Figure 3: Quantification of the expression level of GM2AP in urine samples from lung cancer patients and healthy controls. GM2AP level was quantified by ELISA in urine of the 44 healthy controls and of the 48 lung cancer patients. The expression level of GM2AP was significantly increased from 0.21 ± 0.14 ng/mL in controls to 1.60 ± 1.21 ng/mL in patients. Black bars indicate the average levels for GM2AP in lung cancer patients. *: P value < 0.05 compared to the value for urine samples from healthy controls.](image)

<table>
<thead>
<tr>
<th>n</th>
<th>GM2AP mean ± SD (ng/mL)</th>
<th>P value</th>
</tr>
</thead>
<tbody>
<tr>
<td>All patients</td>
<td>48</td>
<td>1.60 ± 1.21</td>
</tr>
<tr>
<td>Gender</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Male</td>
<td>33</td>
<td>1.16 ± 1.07</td>
</tr>
<tr>
<td>Female</td>
<td>15</td>
<td>1.13 ± 1.05</td>
</tr>
<tr>
<td>Histology</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Adenocarcinoma</td>
<td>25</td>
<td>1.25 ± 1.22</td>
</tr>
<tr>
<td>Small cell lung cancer</td>
<td>15</td>
<td>1.48 ± 1.35</td>
</tr>
<tr>
<td>Squamous cell carcinoma</td>
<td>4</td>
<td>2.27 ± 2.20</td>
</tr>
<tr>
<td>Other type of carcinoma</td>
<td>4</td>
<td>2.99 ± 2.63</td>
</tr>
<tr>
<td>Phatologic stage</td>
<td></td>
<td></td>
</tr>
<tr>
<td>III</td>
<td>7</td>
<td>1.69 ± 1.54</td>
</tr>
<tr>
<td>IV</td>
<td>41</td>
<td>0.63 ± 0.38</td>
</tr>
</tbody>
</table>

Table1: Quantification of the GM2AP level in lung cancer patient urine samples by ELISA.
of lung cancer patients compared to healthy controls (Figure 2), consistent with the increase in protein spot intensity observed in the 2-DE gel. Moreover, using an ELISA for the quantification of GM2AP in urine samples, we then found that the expression level of GM2AP was significantly correlated with only histology cancer types (Table 1). An overexpression of GM2AP level was observed in 54.2% of patients with adenocarcinoma, 29.2% of patients with small cell lung cancer, 8.3% of patients with squamous cell carcinoma, and 8.3% of patients with other carcinoma. The present study also showed the urinary GM2AP level to be significantly higher in patients with squamous cell carcinoma than in those with adenocarcinoma and small cell lung cancer, whereas age, gender and pathologic stage were not correlated in our study. Therefore, the expression level of GM2AP might be a useful determinant for histology cancer type prognosis of lung cancer.

Interestingly, GM2AP is a glycoprotein that was significantly increased in lung cancer urine is one of the key factors involved in the developmental process of lung cancer. The glycosylation change in the glycan moieties of glycoproteins may provides opportunities to discover new biomarkers for cancer diagnosis and treatment [26]. The discovery of the cancer-associated modifications of glycans on the glycoproteins may also improve on the specificity of existing cancer biomarkers [27,28]. However, the glycan structure of urinary GM2AP in lung cancer patient has not been reported. In this study, first we used MALDI-TOF/MS analysis to confirm the intact protein mass of GM2AP in lung cancer urine samples. The molecular mass of GM2AP was higher than that of the predicted protein mass, which was a revealed marker ion characteristic of glycosylation modification. N-linked glycosylation is the most common form of glycosylation that found in eukaryotes. It is occurs when glycans are attached to asparagine residues on the core protein. Therefore, the N-linked glycan structure of urinary GM2AP in lung cancer patients was determined using nanoLC-MS/MS analysis. The glycopeptides ions of GM2AP can be fragmented efficiently by the HCD feature of a linear LTQ Orbitrap hybrid mass spectrometer. An attractive aspect of this dissociation option is the generation of distinct Y ions (peptide plus one HexNAc), thus allowing unequivocal assignment of N-glycosylation sites of glycoproteins. As a result, the common glycan oxonium ions in addition to the Y ion were also detected. We found that the N-glycan structure of GM2AP was corresponded to the structure of (Hex), (HexNAc), (Fuc), linked with peptide (PIIVOGNVTLSVVG) (Figure 4). In general, N-glycosylated proteins comprise a conserved core structure consisting of two N-acetylglycosamine residues linked to asparagine followed by three branched mannose residues [21]. It is first synthesized as a precursor which is then glycosylated, modified and cleaved at Ser to be in the mature form. GM2AP is acting as a cofactor essential that contains at least three functional features including a hydrophobic pocket called the ß-cup structure, an oligosaccharide binding site, and an area that interacts with Hex A for the vivo degradation of ganglioside GM2 to GM3 [22,23]. The critical in vivo role that is played by this activator protein is demonstrated by the occurrence of the AB variant form of GM2 gangliosidosis, a severe lysosomal storage disease cause by a lack of a functional activator protein [24]. Moreover, the inherited deficiency of GM2AP was also related to the changing level of ganglioside and tumor associated gangliosides important in cancer progression. Tumor-associated gangliosides are a result of initial oncogenic transformation and play a role in the induction of invasion and metastasis [16,17]. Tumor cells are synthesized and shed gangliosides into their microenvironments leading to elevated levels of tumor-associated gangliosides in the serum [25]. Changes in the amounts of gangliosides in serum can influence the rate of tumor growth through an undetermined mechanism [15].

In order to identify a potential of GM2AP as biomarker of lung cancer, Western blot analysis was used to confirm and support our results. In this study, the patients had no disorder of renal function as revealed by normal urine creatinine and blood urea nitrogen. The finding the expression level of GM2AP was increased in each subtype
control have no this protein that excrete to urine. Some studies have demonstrated that most glycans are degraded in lysosomes by highly ordered and specific pathways employing endo- and exoglycosidases, sometimes aided by glycoproteins. Thus, the loss of enzyme and/or GM2AP degradation could lead to the accumulation of substances in patient tissue and the appearance in urine [29]. For example, the removal of core fucose (Fucα-1,6GlcNAc) and probably any peripheral fucose residues linked to the outer branches of the chain (e.g., Fucα-1,3GlcNAc) appears to be the first step in degradation because patients lacking this enzyme still have intact N-glycan bound to asparagines [30]. Moreover, many reports suggest that structural changes in cell surface carbohydrates may promote tumor transformation. Dennis et al. [26] reported the α-1,6 linked fucosylation of complex-type glycans may be an important feature of tumor progression related to increased metastasis [31]. Therefore, these preliminary findings suggest that the GM2AP may be useful as a potential urinary marker to monitor lung cancer progression.

However, the secretory mechanism and biological function of GM2AP that associated with lung cancer progression needs further work.

Conclusion

The identification of urinary proteomics developed in this study can serve as an ideal efficient method to establish a panel of potential biomarkers. This study revealed that the urinary GM2AP was increased in lung cancer patients compared to healthy controls. The expression level of GM2AP was validated by Western blot and quantified using ELISA to be significantly higher in lung cancer patients. Additional study on MS provided evidence of an increase of GM2AP glycosylation. Cancer-associated aberrations in glycosylation of glycoprotein can add to the knowledge on existing cancer biomarkers. Therefore, we suggest that the urinary GM2AP may be useful as a marker for lung cancer diagnosis.

Acknowledgements

We gratefully acknowledge the Maharaj Nakron Chiang Mai Hospital, Chiang Mai, Thailand for providing urine samples, Institute of Biological Chemistry, Academia Sinica, Taipei, Taiwan for general support in this work, GRC Mass Core Facility of Genomics Research Center, Academia Sinica, Taipei, Taiwan for mass spectrometry analysis, respectively. This research was supported by a National Health Research Institute grant (NHRI-E098-9702BI), National Science Council grant (NSC 91-3112-P-001-009-Y) and Academia Sinica grant. We also thank the Maharaj Nakron Chiang Mai Hospital, Chiang Mai, Thailand for partial financial support.

References
